Studying human brain tissue in 3D
An international team has developed a cutting-edge technique, enabling human brain tissue to be studied in 3D.
Investing in a new treatment to improve symptoms and slow Parkinson’s
Parkinson's UK is pleased to announce a new project worth £1.2million to fund essential research towards new treatment that could both improve symptoms and slow the progression of Parkinson's.
Calcium may play a role in Parkinson's
New international research suggests that too much calcium inside brain cells may trigger a chain reaction that leads to Parkinson's.
Investing in a new treatment for dyskinesia
We're partnering with US company Neurolixis to accelerate the development of a drug that could prevent dyskinesia, a debilitating side effect of Parkinson's medication.
Research into flu and the onset of Parkinson's
A study, featured in the Daily Mail, suggests a link between certain types of flu and risk of Parkinson's.
Pfizer pulls neuroscience projects
International pharmaceutical company, Pfizer, has announced a move to end all early-stage projects in neuroscience.
More than 12,000 Scots living with Parkinson's and numbers continue to rise
New figures from Parkinson's UK show that more than 12,000 Scots are now living with Parkinson's, and numbers are continuing to rise.
Parkinson's diagnoses set to increase by a fifth by 2025
The number of people diagnosed and living with Parkinson’s is increasing, according to our latest research.
Research on caffeine to diagnose Parkinson's
Researchers in Japan have discovered that people with Parkinson's may have lower levels of caffeine in their blood after drinking tea and coffee.
Researchers discover toxic form of alpha-synuclein
New research demonstrates how the protein alpha-synuclein could cause the loss of cells in Parkinson’s.